Diclofenac Use in Teenagers

Regulatory Status and Approval

The Pan-American League of Associations for Rheumatology acknowledges that diclofenac can be used in children and adolescents at physician discretion when other approved NSAIDs are contraindicated or unavailable 1
Diclofenac lacks FDA or EMA approval for pediatric patients, distinguishing it from other NSAIDs that have established pediatric indications 1

Naproxen is the preferred first-line NSAID for teenagers with inflammatory conditions due to its evidence-supported efficacy and safety profile in pediatric populations 1
The American Academy of Pediatrics recommends ibuprofen as the safest NSAID option for non-inflammatory pain conditions in adolescents, with the lowest risk of serious gastrointestinal complications 2, 3
Alternative FDA-approved NSAIDs include: ibuprofen, indomethacin, meloxicam, tolmetin, etodolac, ketorolac, oxaprozin, and celecoxib 1

Gastrointestinal complications are the most frequent adverse effects, requiring gastroprotective agents in high-risk patients 4, 5
Risk factors warranting gastroprotection include: history of peptic ulcer disease, GI bleeding, concurrent anticoagulant/antiplatelet use, or prolonged high-dose therapy 6
NSAIDs may delay natural healing processes by suppressing inflammation necessary for tissue recovery 4

Start with non-NSAID analgesics (acetaminophen up to 4 g daily) for non-inflammatory pain 7, 5
If inadequate relief, use ibuprofen (starting at 1200 mg/day) as the safest NSAID option 2, 3, 5
For inflammatory conditions, prefer naproxen as first-line NSAID therapy 1
Consider diclofenac only when FDA-approved pediatric NSAIDs are contraindicated or ineffective, under rheumatology guidance, or when benefits clearly outweigh the lack of pediatric approval data 1

Never combine diclofenac with other NSAIDs, as this increases adverse effects without additional benefit 6, 5
Do not use in patients with active GI bleeding, severe renal impairment, or decompensated heart failure 6
Different diclofenac formulations are not bioequivalent even at the same milligram strength 4
Avoid starting diclofenac before trying acetaminophen and ibuprofen in non-inflammatory conditions 5
Do not delay initiation of disease-modifying therapy when using NSAIDs for juvenile idiopathic arthritis 1